Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support

[1]  N. Kadowaki,et al.  Bendamustine and G-CSF support , 2019, Supportive Care in Cancer.

[2]  S. Cuzzocrea,et al.  Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. , 2018, The oncologist.

[3]  A. Collins,et al.  Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database , 2017, Supportive Care in Cancer.

[4]  F. Pane,et al.  A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide , 2017, Clinical case reports.

[5]  F. Pane,et al.  Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience , 2016, Supportive Care in Cancer.

[6]  F. Pane,et al.  Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma , 2016, Case reports in hematology.

[7]  F. Pane,et al.  Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone , 2016, Supportive Care in Cancer.

[8]  F. Pane,et al.  Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience , 2015, Supportive Care in Cancer.

[9]  L. Balducci,et al.  Increased risk of myelotoxicity in elderly patients with non‐Hodgkin lymphoma , 2004, Cancer.